Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial

被引：8

作者：

Smit, E. F. ^{[1
]}

Felip, E. ^{[2
,3
]}

Uprety, D. ^{[4
]}

Nakagawa, K. ^{[5
]}

Paz-Ares, L. ^{[6
]}

Pacheco, J. ^{[7
,8
]}

Li, B. T. ^{[9
]}

Planchard, D. ^{[10
]}

Baik, C. ^{[11
]}

Goto, Y. ^{[12
]}

Murakami, H. ^{[13
]}

Saltos, A. ^{[14
]}

Saxena, K. ^{[15
]}

Shiga, R. ^{[16
]}

Cheng, Y. ^{[17
]}

Yan, Q. ^{[18
]}

Feng, W. ^{[19
]}

Janne, P. A. ^{[20
,21
]}

机构：

[1] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands

[2] Vall Hebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain

[3] Vall Hebron Inst Oncol, Barcelona, Spain

[4] Barbara Ann Karmanos Canc Inst, Med Oncol, Detroit, MI USA

[5] Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan

[6] Univ Navarra, Dept Med Oncol, Univ Navarra Clin, Navarra, Spain

[7] Univ Colorado Anschutz, Internal Med, Aurora, CO USA

[8] Univ Colorado Anschutz, Div Med Oncol, Aurora, CO USA

[9] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[10] Gustave Roussy, Med Oncol, Thorac Team, Villejuif, France

[11] Univ Washington, Thorac Head & Neck Med Oncol, Seattle, WA USA

[12] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan

[13] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[14] H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol, Tampa, FL USA

[15] Daiichi Sankyo Inc, R&D, Basking Ridge, NJ USA

[16] Daiichi Sankyo Inc, Global Oncol R&D, Basking Ridge, NJ USA

[17] Daiichi Sankyo Inc, Clin Safety & Pharmacovigilance, Basking Ridge, NJ USA

[18] Daiichi Sankyo Inc, Biostat, Basking Ridge, NJ USA

[19] Daiichi Sankyo Inc, Global Compan Diagnost, Basking Ridge, NJ USA

[20] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA

[21] Belfer Ctr Appl Canc Sci, Boston, MA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.1103

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

975P

引用

页码：S994 / S995

页数：2

共 50 条

[1] Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
Nakagawa, K.
Nagasaka, M.
Felip, E.
Pacheco, J.
Baik, C.
Goto, Y.
Saltos, A.
Li, B.
Udagawa, H.
Gadgeel, S.
Murakami, H.
Planchard, D.
Bazhenova, L.
Paz-Ares, L.
Perol, M.
Mazieres, J.
Barlesi, F.
Saxena, K.
Shiga, R.
Acharyya, S.
Cheng, Y.
Shahidi, J.
Janne, P.
Smit, E.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S109 - S110
[2] Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01
Smit, E.
Nakagawa, K.
Nagasaka, M.
Felip, E.
Goto, Y.
Li, B.
Pacheco, J.
Murakami, H.
Barlesi, F.
Saltos, A.
Perol, M.
Udagawa, H.
Saxena, K.
Shiga, R.
Guevara, F.
Acharyya, S.
Shahidi, J.
Planchard, D.
Janne, P.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S173 - S173
[3] Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Smit, Egbert F.
Felip, Enriqueta
Uprety, Dipesh
Nagasaka, Misako
Nakagawa, Kazuhiko
Rodriguez, Luis Paz-Ares
Pacheco, Jose M.
Li, Bob T.
Planchard, David
Baik, Christina
Goto, Yasushi
Murakami, Haruyasu
Saltos, Andreas
Pereira, Kaline
Taguchi, Ayumi
Cheng, Yingkai
Yan, Qi
Feng, Wenqin
Tsuchihashi, Zenta
Janne, Pasi A.
[J]. LANCET ONCOLOGY, 2024, 25 (04): : 439 - 454
[4] Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01
Li, B. T.
Smit, E. F.
Goto, Y.
Nakagawa, K.
Goto, K.
Mazieres, J.
Uprety, D.
Bazhenova, L.
Saltos, A.
Felip, E.
Pacheco, J.
Perol, M.
Paz-Ares, L.
Saxena, K.
Shiga, R.
Cheng, Y.
Yan, Q.
Planchard, D.
Janne, P. A.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S995 - S996
[5] Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)
Li, B. T.
Smit, E. F. F.
Goto, Y.
Nakagawa, K.
Udagawa, H.
Mazieres, J.
Nagasaka, M.
Bazhenova, L.
Saltos, A. N.
Felip, E.
Pacheco, J. M.
Perol, M.
Paz-Ares, L.
Saxena, K.
Shiga, R.
Cheng, Y.
Acharyya, S.
Shahidi, J.
Planchard, D.
Janne, P. A.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S1323 - S1324
[6] DESTINY-Lung01 Trial Investigators Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
Sharayah, Ahmad
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209 (06) : 749 - 750
[7] Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
Goto, K.
Sang-We, K.
Kubo, T.
Goto, Y.
Ahn, M-J.
Planchard, D.
Kim, D-W.
Yang, J. C-H.
Yang, T-Y.
Pereira, K. M. C.
Saxena, K.
Shiga, R.
Cheng, Y.
Aregay, M.
Janne, P. A.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1422 - S1422
[8] Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC)
Khatri, Amit
Cobbina, Enoch
Cheng, Shen
Abutarif, Malaz
Garimella, Tushar
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02
Janne, P.
Goto, Y.
Kubo, T.
Ninomiya, K.
Kim, S. -W.
Planchard, D.
Ahn, M. -J.
Smit, E. F.
de Langen, A. J.
Perol, M.
Pons-Tostivint, E.
Novello, S.
Hayashi, H.
Shimizu, J.
Kim, D. -W.
Pereira, K.
Cheng, F. -C.
Taguchi, A.
Cheng, Y.
Goto, K.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S148 - S148
[10] Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study
Smit, Egbert F.
[J]. FUTURE ONCOLOGY, 2024,

← 1 2 3 4 5 →